1,092 reports of this reaction
6.9% of all FAM TRASTUZUMAB DERUXTECAN NXKI reports
#1 most reported adverse reaction
NAUSEA is the #1 most commonly reported adverse reaction for FAM TRASTUZUMAB DERUXTECAN NXKI, manufactured by Daiichi Sankyo Inc.. There are 1,092 FDA adverse event reports linking FAM TRASTUZUMAB DERUXTECAN NXKI to NAUSEA. This represents approximately 6.9% of all 15,771 adverse event reports for this drug.
Patients taking FAM TRASTUZUMAB DERUXTECAN NXKI who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among FAM TRASTUZUMAB DERUXTECAN NXKI users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for FAM TRASTUZUMAB DERUXTECAN NXKI:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,092 FDA reports for FAM TRASTUZUMAB DERUXTECAN NXKI. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 6.9% of all adverse event reports for FAM TRASTUZUMAB DERUXTECAN NXKI, making it one of the most commonly reported side effect.
If you experience nausea while taking FAM TRASTUZUMAB DERUXTECAN NXKI, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.